PRRT2 and COVID-19: Here we show for the first time that NETs are elevated in response to lipopolysaccharide (LPS) from neutrophils isolated from hospitalised patients with COVID-19 and that the orally active protein kinase C (PKC) inhibitor, ruboxistaurin (LY-333531), is a potent inhibitor of NETosis in this cohort.